CHA AI Healthkare Co.,Ltd. (025620) AI Stock Analysis

CHA AI Healthkare Co.,Ltd.

(Korea Exchange:025620)

Select Model

Rating:49Neutral

Price Target:KRW 5,323.00▲(5.20% Upside)

Action:initiatedcoverage

Date:10/28/26

The score is held back primarily by weak financial quality—negative operating profitability and consistently negative operating/free cash flow despite a large TTM net income swing—raising concerns about sustainability. Technical indicators are moderately supportive in the near term (positive MACD, neutral RSI, price above 50DMA), and valuation is roughly mid-range on P/E, but neither is strong enough to offset the cash-flow and operating-margin risks.

Positive Factors

TTM Revenue ReboundThe strong TTM revenue rebound indicates that demand and operating activity have recovered from prior weakness. If maintained, a larger revenue base could improve fixed-cost absorption and create a foundation for restoring profitability, although current margins remain pressured.

Negative Factors

Persistent Cash BurnPersistent negative operating and free cash flow means reported activity is not translating into internally generated funding. Continued cash consumption can restrict investment, increase reliance on external financing, and weaken resilience unless cash conversion improves materially.

CHA AI Healthkare Co.,Ltd. (025620) vs. SPDR S&P 500 ETF (SPY)

Market Cap: KRW 92.06B
Dividend Yield: ―
Average Volume (3M): 9,188
Price to Earnings (P/E): 17.1
Beta (1Y): 0.38
Revenue Growth: -5.37%
EPS Growth: ―
Country: KR
Employees: 44
Sector: General
Sector Strength: 55
Industry: Household & Personal Products

CHA AI Healthkare Co.,Ltd. Business Overview & Revenue Model

Company Description

Based in Incheon, South Korea, CHA AI Healthkare Co., Ltd. is a cosmetics company that produces and distributes a wide array of beauty products. Established on June 30, 1972, its offerings encompass various skincare and makeup essentials, including s...

CHA AI Healthkare Co.,Ltd. Financial Statement Overview

Summary

Revenue rebounded strongly in TTM, but core profitability remains weak with deeply negative EBIT/EBITDA margins. Reported TTM net income appears influenced by non-operating items, while operating cash flow and free cash flow are negative across all periods, indicating poor earnings-to-cash conversion. Balance sheet leverage is only moderate, but rising debt and historically volatile returns add risk if cash burn persists.

Income Statement

28Negative

Balance Sheet

52Neutral

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.43B	7.31B	15.68B	16.09B	6.25B	14.98B
Gross Profit	1.71B	1.33B	7.35B	7.98B	904.53M	716.44M
EBITDA	-7.13B	-6.95B	-7.59B	-8.90B	-7.03B	-16.39B
Net Income	8.14B	1.37B	-9.49B	-6.80B	-21.43B	-38.67B
Balance Sheet
Total Assets	121.68B	110.25B	38.92B	48.36B	48.39B	79.88B
Cash, Cash Equivalents and Short-Term Investments	15.18B	41.66B	4.01B	5.00B	10.50B	8.30B
Total Debt	40.74B	30.56B	5.29B	2.78B	2.75B	8.60B
Total Liabilities	40.68B	34.82B	9.28B	8.37B	6.81B	19.75B
Stockholders Equity	81.00B	75.44B	29.65B	40.00B	41.59B	59.78B
Cash Flow
Free Cash Flow	-6.13B	-6.71B	-7.16B	-9.95B	-12.97B	-9.59B
Operating Cash Flow	-6.01B	-6.71B	-6.91B	-9.86B	-4.98B	-3.49B
Investing Cash Flow	-76.46B	-35.95B	2.23B	-184.69M	9.43B	-16.31B
Financing Cash Flow	83.34B	80.17B	1.94B	4.35B	-2.29B	26.55B

CHA AI Healthkare Co.,Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price5060.00

Price Trends

50DMA5044.30Positive

100DMA5385.45Negative

200DMA7416.38Negative

Market Momentum

MACD50.40Positive

RSI42.38Neutral

STOCH29.97Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:025620, the sentiment is Negative. The current price of 5060.00 is below the 20-day moving average (MA) of 5350.50, above the 50-day MA of 5044.30, and below the 200-day MA of 7416.38, indicating a neutral trend. The MACD of 50.40 indicates Positive momentum. The RSI at 42.38 is Neutral, neither overbought nor oversold. The STOCH value of 29.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:025620.

CHA AI Healthkare Co.,Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

KR:025620 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KR:044820	65Neutral	KRW 209.73B	3.78	―	3.55%	25.12%	295.70%
KR:192820	60Neutral	KRW 2.80T	14.58	―	1.34%	15.81%	197.32%
KR:002790	58Neutral	KRW 1.98T	16.78	―	1.57%	8.62%	13.98%
KR:161890	56Neutral	KRW 2.66T	14.36	―	0.77%	12.57%	90.44%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
KR:200130	50Neutral	KRW 204.92B	-243.15	―	0.81%	-8.83%	-111.22%
KR:025620	49Neutral	KRW 92.06B	17.13	―	―	-5.37%	―

* General Sector Average

Performance Comparison

KR:025620 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
KR:025620	CHA AI Healthkare Co.,Ltd.	5060.00	-8110.00	-61.58%
KR:002790	AMOREPACIFIC Holdings Corp.	25400.00	296.85	1.18%
KR:044820	Cosmax BTI Inc.	21950.00	8814.85	67.11%
KR:161890	KOLMAR KOREA CO. LTD	112500.00	37423.84	49.85%
KR:192820	COSMAX, Inc.	247000.00	48251.70	24.28%
KR:200130	KolmarBNH Co., Ltd.	7410.00	-6179.50	-45.47%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 28, 2026

CHA AI Healthkare Co.,Ltd. AI Stock Analysis